At what pace is the next generation immunotherapies market growing, and what is its estimated value?
The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.54 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to rising pervasiveness of oncology, increase in research and development investments, rise in government initiatives, rising government expenditure on health, and expanding indications.
The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $238.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing prevalence of cancer, rising healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) t-cell therapy, rising burden of chronic diseases, and increasing research in the area of next-generation drugs. Major trends in the forecast period include shift toward combination therapies, technological advancements, innovation in therapeutic approaches, advancements in personalized medicine, and regulatory support advancements.
Get Your Free Sample of The Global Next Generation Immunotherapies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What are the top drivers to the rising demand in the next generation immunotherapies market?
The increasing prevalence of cancer is expected to propel the growth of the next-generation immunotherapies market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The prevalence of cancer is due to factors such as aging populations, lifestyle changes, environmental exposures, and improved detection methods. Next-generation immunotherapies provide advanced, targeted treatments that enhance the body’s immune response to cancer, offering greater effectiveness, durability, and personalization. For instance, in May 2024, according to the reports published by the National Cancer Institute (NCI), a US-based government agency, in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. Therefore, the increasing prevalence of cancer is driving the growth of next-generation immunotherapies market.
How is the next generation immunotherapies market segmented?
The next generation immunotherapies market covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates – ADC’s, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC’s): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors
Order your report now for swift delivery
Who are the top competitors in the next generation immunotherapies market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
What significant trends should we anticipate in the next generation immunotherapies market over the forecast period?
Major companies operating in the next-generation immunotherapies market are focusing on developing innovative therapies, such as CAR T-cell therapy, to treat cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is a type of immunotherapy where a patient’s T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, launched Qartemi, an India’s first CAR T-cell therapy. This therapy is for adult B-cell non-Hodgkin lymphoma, genetically modifying a patient’s immune cells to target and destroy cancer cells, offering a highly effective and personalized treatment option. It provides renewed hope to patients for whom conventional treatments have proven ineffective, with the advantage of being more affordable than similar global options.
Which regional trends are influencing the next generation immunotherapies market, and which area dominates the industry?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Next Generation Immunotherapies Market Report 2025 Offer?
The next generation immunotherapies market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Next-generation immunotherapies refer to advanced treatments designed to enhance the body’s immune system to fight diseases, particularly cancer, with improved precision, efficacy, and safety. These therapies go beyond traditional immune-based treatments by leveraging cutting-edge technologies and aim to overcome earlier immunotherapies’ limitations, reduce side effects, and offer long-lasting immune responses.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
